CAR T-cell Therapies for Multiple Myeloma

Aug 24, 2026

Summary In August 2026, the FDA granted accelerated approval to Bristol Myers Squibb’s ZENBEXUS (iberdomide), the first-in-class CELMoD, in combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy. Approval rests on the Phase 3 EXCAL...

May 18, 2026

Summary Multiple myeloma remains one of oncology's most challenging blood cancers, but the treatment landscape is undergoing a seismic shift.  With the multiple myeloma market valued at USD 28.7 billion in 2025 and projected to grow steadily through 2036, the pipeline has never been more robust or more conse...

Apr 02, 2025

Multiple myeloma, a complex blood cancer rooted in the bone marrow, affects 160K people globally each year, with a mortality rate of 106K. According to DelveInsight, nearly 75K new cases were reported across seven major markets in 2023, a figure expected to climb in the coming years. Yet, amid these sobering statis...

Mar 14, 2025

The success of CAR-T therapies like Bristol-Myers Squibb/Bluebird bio’s ABECMA and Janssen’s CARVYKTI is reshaping treatment paradigms, challenging traditional options like stem cell transplants and proteasome inhibitors. The multiple myeloma market size in the US is responding rapidly from ~USD 15 billion, with in...